Combining poly-arginine with the hydrophobic counter-anion 4-(1-pyrenyl)-butyric acid for protein transduction in transdermal delivery

Biomaterials

Volumn 33, Issue 27, 2012, Pages 6468-6475

  Candan, Gerile ^a   Michiue, Hiroyuki ^a   Ishikawa, Sanae ^a   Fujimura, Atsushi ^a   Hayashi, Keiichiro ^a   Uneda, Atsuhito ^a   Mori, Akiko ^a   Ohmori, Iori ^a   Nishiki, Tei ichi ^a   Matsui, Hideki ^a   Tomizawa, Kazuhito ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Hydroquinone; Poly arginine; Protein transduction; Tat; Transdermal delivery; Tyrosinase inhibitor

Indexed keywords

HYDROQUINONE; POLY-ARGININE; PROTEIN TRANSDUCTION; TAT; TRANSDERMAL DELIVERY; TYROSINASE INHIBITORS;

ARGININE; BACTERIOPHAGES; BUTYRIC ACID; CELL CULTURE; DRUG THERAPY; HYDROPHILICITY; HYDROPHOBICITY; KETONES; PHENOLS;

PROTEINS;

BUTYRIC ACID; GREEN FLUORESCENT PROTEIN; HYDROQUINONE; MELANIN; POLYARGININE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; EPIDERMIS; FEMALE; GUINEA PIG; HYDROPHOBICITY; HYPERPIGMENTATION; IN VIVO STUDY; MELANOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN PENETRATION; SKIN PERMEABILITY; SYNTHESIS; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; ULTRAVIOLET IRRADIATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANIONS; BUTYRIC ACID; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; GREEN FLUORESCENT PROTEINS; GUINEA PIGS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYDROQUINONES; MELANINS; MELANOMA, EXPERIMENTAL; MICE; PEPTIDES; PYRENES; SKIN PIGMENTATION; ULTRAVIOLET RAYS;

CAVIA;

EID: 84863598843     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.04.056     Document Type: Article

References (30)

1. Liu C.H., Chang F.Y. Development and characterization of eucalyptol microemulsions for topic delivery of curcumin. Chem Pharm Bull 2011, 59:172-178.
2. Kogan A., Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci 2006, 123-126:369-385.
3. Matsui H., Tomizawa K., Lu Y.F., Matsushita M. Protein therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery. Curr Protein Pept Sci 2003, 4:151-157.
4. Tomoda K., Terashima H., Suzuki K., Inagi T., Terada H., Makino K. Enhanced transdermal delivery of indomethacin-loaded PLGA nanoparticles by iontophoresis. Colloids Surf B Biointerfaces 2011, 88:706-710.
5. Shah V.P., Behl C.R., Flynn G.L., Higuchi W.I., Schaefer H. Principles and criteria in the development and optimization of topical therapeutic products. J Pharm Sci 1992, 81:1051-1054.
6. Nino M., Calabrò G., Santoianni P. Topical delivery of active principles: the field of dermatological research. Dermatol Online J 2010, 16:4.
7. Korting H.C., Stolz W., Schmid M.H., Maierhofer G. Interaction of liposomes with human epidermis reconstructed in vitro. Br J Dermatol 1995, 132:571-579.
8. Schwarze S.R., Hrusk K.A., Dowdy S.F. Protein transduction: unrestricted delivery into all cells?. Trends Cell Biol 2000, 10:290-295.
9. Special theme issue on membrane permeable peptide vectors: chemistry and functional design for the therapeutic application 2008, vol. 60:447-614. Adv drug delivery Rev.
10. Joliot A., Prochiantz A. Transduction peptides: from technology to physiology. Nat Cell Biol 2004, 6:189-196.
11. Wadia J.S., Stan R.V., Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004, 10:310-315.
12. Takeuchi T., Kosuge M., Tadokoro A., Sugiura Y., Nishi M., Kawata M. Direct and rapid cytosolic delivery using cell-penetrating peptides mediated by pyrenebutyrate. ACS Chem Biol 2006, 1:299-303.
13. Guterstam P., Madani F., Hirose H., Takeuchi T., Futaki S., El Andaloussi S. Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochim Biophys Acta 2009, 1788:2509-2517.
14. Westerhof W., Kooyers T.J. Hydroquinone and its analogues in dermatology-a potential health risk. J Cos Dermatol 2005, 4:55-59.
15. Nordlund J.J., Grimes P.E., Ortonnes J.P. The safety of hydroquinone. J Eur Acad Dermatol Venereol 2006, 20:781-787.
16. Chen Y.R., Y-Y R., Lin T.Y., Huang C.P., Tang W.C., Chen S.T. Identification of an alkylhydroquinone from Rhus succedanea as an inhibitor of tyrosinase and melanogenesis. J Agric Food Chem 2009, 57:2200-2205.
17. Matsushita M., Tomizawa K., Moriwaki A., Li S.T., Terada H., Matsui H. A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J Neurosci 2001, 21:6000-6007.
18. Takenobu T., Tomizawa K., Matsushita M., Li S.T., Moriwaki A., Lu Y.F. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther 2002, 1:1043-1049.
19. Fujita H., Motokawa T., Katagiri T., Yokota S., Yamamoto A., Himeno M. Inulavosin, a melanogenesis inhibitor, leads to mistargeting of tyrosinase to lysosomes and accelerates its degradation. J Invest Dermatol 2009, 129:1489-1499.
20. Kim J.H., Baek S.H., Kim D.H., Choi T.Y., Yoon T.J., Hwang J.S. Downregulation of melanin synthesis by haginin A and its application to in vivo lightening model. J Invest Dermatol 2008, 128:1227-1235.
21. Park K.T., Ki J.K., Hwang D., Yoo Y., Lim Y.H. Inhibitory effect of mulberroside A and its derivatives on melanogenesis induced by ultraviolet B irradiation. Food Chem Toxicol 2011, 49:3038-3045.
22. Maeda K., Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther 1996, 276:765-769.
23. Kim H., Choi H.R., Kim D.S., Park K.C. Topical hypopigmenting agents for pigmentary disorders and their mechanisms of action. Ann Dermatol 2012, 24:1-6.
24. Hwang J.S., Lee H.Y., Lim T.Y., Kim M.Y., Yoon T.J. Disruption of tyrosinase glycosylation by N-acetylglucosamine and its depigmenting effects in guinea pig skin and in human skin. J Dermatol Sci 2011, 63:199-201.
25. van den Berg A., Dowdy S.F. Protein transduction domain delivery of therapeutic macromolecules. Curr Opin Biotechnol 2011, 22:888-893.
26. Rothbard J.B., Garlington S., Lin Q., Kirschberg T., Kreider E., Mcgrane P.L. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 2000, 6:1253-1257.
27. Hou Y.W., Chan M.H., Hsu H.R., Liu B.R., Chen C.P., Chen H.H. Transdermal delivery of proteins mediated by non-covalently associated arginine-rich intracellular delivery peptides. Exp Dermatol 2007, 16:999-1006.
28. Lopes L.B., Furnish E., Komalavilas P., Seal B.L., Panitch A., Bentley M.V. Enhanced skin penetration of P20 phosphopeptide using protein transduction domains. Eur J Pharm Biopharm 2008, 68:441-445.
29. Kang M.J., Eum J.Y., Park S.H., Kang M.H., Park K.H., Choi S.E. Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice. Int J Pharm 2010, 402:198-204.
30. Denissenko M.F., Pao A., Tang M., Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996, 274:430-432.